Hundreds of Massachusetts jobs impacted by Takeda’s restructuring plan
Takeda, the Tokyo-based pharmaceutical company with a major hub in Cambridge, is making changes that will impact hundreds of jobs in Massachusetts and across the country. Last week, the company announced an organizational restructuring plan aimed at saving more than JPY 200 billion by the 2028 fiscal year, “through streamlining of corporate functions, bringing leadership and teams closer to patients and customers and process simplification made possible by advanced technologies.”On Monday, a company spokesperson confirmed Takeda had filed a Worker Adjustment and Retraining Notification Act notice that estimates 247 roles in Massachusetts and 387 in other U.S. states will be impacted by the upcoming changes. “These changes are designed to further standardize and simplify ways of working so we can prioritize more resources and strategic technology investments to advance our late‑stage pipeline and prepare for multiple launches, including oveporexton, rusfertide and zasocitinib,” the spokesperson said. Impacted employees will be given support in identifying other potential opportunities within the company, the spokesperson said. Takeda is currently seeking to fill about 700 jobs, including nearly 300 in Massachusetts.
Takeda, the Tokyo-based pharmaceutical company with a major hub in Cambridge, is making changes that will impact hundreds of jobs in Massachusetts and across the country.
Last week, the company announced an organizational restructuring plan aimed at saving more than JPY 200 billion by the 2028 fiscal year, “through streamlining of corporate functions, bringing leadership and teams closer to patients and customers and process simplification made possible by advanced technologies.”
On Monday, a company spokesperson confirmed Takeda had filed a Worker Adjustment and Retraining Notification Act notice that estimates 247 roles in Massachusetts and 387 in other U.S. states will be impacted by the upcoming changes.
“These changes are designed to further standardize and simplify ways of working so we can prioritize more resources and strategic technology investments to advance our late‑stage pipeline and prepare for multiple launches, including oveporexton, rusfertide and zasocitinib,” the spokesperson said.
Impacted employees will be given support in identifying other potential opportunities within the company, the spokesperson said. Takeda is currently seeking to fill about 700 jobs, including nearly 300 in Massachusetts.
